Fri Jan 24 12:00:00 UTC 2025: ## Novo Nordisk Stock: Still a Buy Despite Wegovy Setback?
**New York, NY** – Despite a recent decline in its stock price, pharmaceutical giant Novo Nordisk (NVO) remains a compelling long-term investment, according to a new analysis by The Motley Fool. While the company’s flagship weight-loss drug, Wegovy, recently faced a blow from a clinical trial showing Eli Lilly’s (LLY) competing drug, Mounjaro, to be more effective, the analysis argues that Novo Nordisk’s market position remains strong for now.
Wegovy currently holds a 73% share of the global anti-obesity medicine market. However, a recent head-to-head clinical trial revealed that Mounjaro resulted in significantly greater weight loss (20.2% vs. 13.7%). This news caused a dip in Novo Nordisk’s stock price, which is down over 20% in the last year.
Despite this setback, The Motley Fool highlights several mitigating factors. Currently, supply constraints for both Wegovy and Mounjaro limit the immediate impact of Mounjaro’s superior efficacy. Eli Lilly is struggling to meet the massive demand for Mounjaro, meaning a significant portion of the market will remain reliant on Wegovy. Furthermore, Novo Nordisk is heavily investing in expanding its manufacturing capabilities to alleviate supply issues.
The Motley Fool concludes that while Novo Nordisk’s long-term prospects are no longer guaranteed, the current high demand and supply constraints for both drugs offer a buffer, maintaining a solid investment thesis in the short-to-medium term. However, investors are cautioned to diversify their portfolios and acknowledge the potential for future competitive pressures as the market landscape evolves. The company’s continued success will depend on its ability to innovate and maintain a strong market presence. Further, the future success hinges on upcoming results from Novo Nordisk’s pipeline of new weight-loss medications.
First Piper 